Skip to main content
Erschienen in: Virchows Archiv 2/2019

27.11.2018 | Original Article

Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study

verfasst von: Pollianna Muniz Alves, José Alcides Almeida de Arruda, Diego Antônio Costa Arantes, Sara Ferreira Santos Costa, Lucas Lacerda Souza, Hélder Antônio Rebelo Pontes, Felipe Paiva Fonseca, Ricardo Alves Mesquita, Cassiano Francisco Weege Nonaka, Elismauro Francisco Mendonça, Aline Carvalho Batista

Erschienen in: Virchows Archiv | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to investigate the profile of tumor-infiltrating lymphocytes (TIL) in osteosarcomas of the jaws (OSJ). A total of 21 OSJ samples were analyzed in a retrospective and cross-sectional multicenter study. Immunohistochemistry was performed to determine the recognition of TIL such as CD4+, CD8+, granzyme B+ (GrB), programmed cell death protein+ (PD-1), and cytotoxic T lymphocyte-associated antigen 4+ (CTLA-4) in intratumoral and peripheral (stromal) regions. Positivity was determined based on the percentage and density of TIL+ per square millimeter [1 = absent (< 25 cells/mm2), 2 = low (25 to 130 cells/mm2), and 3 = high (> 130 cells/mm2)]. The association of TIL density with clinicopathologic data was determined by the Mann-Whitney test (p < 0.05). OSJ were positive for CD8+ cells in 45% (n = 9) of cases, for CD4+ cells in 30% (n = 6) of cases, and for CTLA-4+ in 4.8% (n = 1) of cases, with a score of 2 (low TIL) in all cases. All cases were negative for GrB and PD-1 (score 1). No association was observed between immune infiltrate and clinicopathologic findings. OSJ showed a microenvironment with low TIL, including failure of effectiveness of the antitumor immune response (absence of GrB+ cells), and few cells exhibited immunotherapeutic targets, such as CTLA-4 and PD-1.
Literatur
1.
Zurück zum Zitat de Arruda JAA, Silva LVO, Kato CNAO, Schuch LF, Batista AC, Costa NL, Tarquinio SBC, Rivero ERC, Carrard VC, Martins MD, Sobral APV, Mesquita RA (2017) A multicenter study of malignant oral and maxillofacial lesions in children and adolescents. Oral Oncol 75:39–45CrossRefPubMed de Arruda JAA, Silva LVO, Kato CNAO, Schuch LF, Batista AC, Costa NL, Tarquinio SBC, Rivero ERC, Carrard VC, Martins MD, Sobral APV, Mesquita RA (2017) A multicenter study of malignant oral and maxillofacial lesions in children and adolescents. Oral Oncol 75:39–45CrossRefPubMed
2.
Zurück zum Zitat Paparella ML, Olvi LG, Brandizzi D, Keszler A, Santini-Araujo E, Cabrini RL (2013) Osteosarcoma of the jaw: an analysis of a series of 74 cases. Histopathology 63(4):551–557PubMed Paparella ML, Olvi LG, Brandizzi D, Keszler A, Santini-Araujo E, Cabrini RL (2013) Osteosarcoma of the jaw: an analysis of a series of 74 cases. Histopathology 63(4):551–557PubMed
4.
Zurück zum Zitat Chen YM, Shen QC, Gokavarapu S, Ong HS, Cao W, Ji T (2016) Osteosarcoma of the mandible: a site-specific study on survival and prognostic factors. J Craniofac Surg 27(8):1929–1933CrossRefPubMed Chen YM, Shen QC, Gokavarapu S, Ong HS, Cao W, Ji T (2016) Osteosarcoma of the mandible: a site-specific study on survival and prognostic factors. J Craniofac Surg 27(8):1929–1933CrossRefPubMed
5.
Zurück zum Zitat Asioli S, Righi A, Rucci P, Tarsitano A, Marchetti C, Bacchini P, Balbi T, Bertoni F, Foschini MP (2017) p16 protein expression and correlation with clinical and pathological features in osteosarcoma of the jaws: experience of 37 cases. Head Neck 39(9):1825–1831CrossRefPubMed Asioli S, Righi A, Rucci P, Tarsitano A, Marchetti C, Bacchini P, Balbi T, Bertoni F, Foschini MP (2017) p16 protein expression and correlation with clinical and pathological features in osteosarcoma of the jaws: experience of 37 cases. Head Neck 39(9):1825–1831CrossRefPubMed
6.
Zurück zum Zitat Heymann MF, Lézot F, Heymann D (2017) The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol Heymann MF, Lézot F, Heymann D (2017) The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol
7.
Zurück zum Zitat Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, Xiang D, He A (2016) Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep 6:39862CrossRefPubMedPubMedCentral Liu B, Huang Y, Sun Y, Zhang J, Yao Y, Shen Z, Xiang D, He A (2016) Prognostic value of inflammation-based scores in patients with osteosarcoma. Sci Rep 6:39862CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Liu T, Fang XC, Ding Z, Sun ZG, Sun LM, Wang YL (2015) Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS Open Bio 5:682–687CrossRefPubMedPubMedCentral Liu T, Fang XC, Ding Z, Sun ZG, Sun LM, Wang YL (2015) Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS Open Bio 5:682–687CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R (2016) Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093CrossRefPubMedPubMedCentral Koirala P, Roth ME, Gill J, Piperdi S, Chinai JM, Geller DS, Hoang BH, Park A, Fremed MA, Zang X, Gorlick R (2016) Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci Rep 6:30093CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Fritzsching B, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, Machado I, Poeschl J, Lehner B, Szendrõi M, Bosch AL, Bernd L, Csóka M, Mechtersheimer G, Ewerbeck V, Kinscherf R, Kunz P (2015) CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology 4(3):e990800CrossRefPubMedPubMedCentral Fritzsching B, Fellenberg J, Moskovszky L, Sápi Z, Krenacs T, Machado I, Poeschl J, Lehner B, Szendrõi M, Bosch AL, Bernd L, Csóka M, Mechtersheimer G, Ewerbeck V, Kinscherf R, Kunz P (2015) CD8(+)/FOXP3(+)-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology 4(3):e990800CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894CrossRefPubMedPubMedCentral Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889–1894CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W (2018) PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol 11(1):16 Erratum in: J Hematol Oncol 2018;11(1):37CrossRefPubMedPubMedCentral Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W (2018) PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol 11(1):16 Erratum in: J Hematol Oncol 2018;11(1):37CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG (2017) Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent. Oncotarget 8(41):71371–71384PubMedPubMedCentral van Erp AEM, Versleijen-Jonkers YMH, Hillebrandt-Roeffen MHS, van Houdt L, Gorris MAJ, van Dam LS, Mentzel T, Weidema ME, Savci-Heijink CD, Desar IME, Merks HHM, van Noesel MM, Shipley J, van der Graaf WTA, Flucke UE, Meyer-Wentrup FAG (2017) Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent. Oncotarget 8(41):71371–71384PubMedPubMedCentral
16.
Zurück zum Zitat Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F (2017) CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology 6(9):e1331193CrossRefPubMedPubMedCentral Gomez-Brouchet A, Illac C, Gilhodes J, Bouvier C, Aubert S, Guinebretiere JM, Marie B, Larousserie F, Entz-Werlé N, de Pinieux G, Filleron T, Minard V, Minville V, Mascard E, Gouin F, Jimenez M, Ledeley MC, Piperno-Neumann S, Brugieres L, Rédini F (2017) CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology 6(9):e1331193CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Costa Arantes DA, Gonçalves AS, Jham BC, Duarte ECB, de Paula ÉC, de Paula HM, Mendonça EF, Batista AC (2017) Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas. Oral Surg Oral Med Oral Pathol Oral Radiol 123(6):188–196CrossRef Costa Arantes DA, Gonçalves AS, Jham BC, Duarte ECB, de Paula ÉC, de Paula HM, Mendonça EF, Batista AC (2017) Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas. Oral Surg Oral Med Oral Pathol Oral Radiol 123(6):188–196CrossRef
19.
Zurück zum Zitat El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (2017) World Health Organization classification of head and neck tumours. IARC Press, Lyon El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (2017) World Health Organization classification of head and neck tumours. IARC Press, Lyon
20.
21.
Zurück zum Zitat Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141(2):293–302CrossRefPubMed Webb JR, Milne K, Kroeger DR, Nelson BH (2016) PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol 141(2):293–302CrossRefPubMed
22.
Zurück zum Zitat Sundara YT, Kostine M, Cleven AH, Bovée JV, Schilham MW, Cleton-Jansen AM (2017) Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother 66(1):119–128CrossRefPubMed Sundara YT, Kostine M, Cleven AH, Bovée JV, Schilham MW, Cleton-Jansen AM (2017) Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother 66(1):119–128CrossRefPubMed
23.
Zurück zum Zitat Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S (2017) Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget 8(67):111836–111846CrossRefPubMedPubMedCentral Palmerini E, Agostinelli C, Picci P, Pileri S, Marafioti T, Lollini PL, Scotlandi K, Longhi A, Benassi MS, Ferrari S (2017) Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. Oncotarget 8(67):111836–111846CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, Manara MC, Bongiovanni L, Valenti CF, Burocchi A, Parenza M, Cappetti B, Sangaletti S, Tripodo C, Scotlandi K, Colombo MP, Chiodoni C (2017) Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors. Clin Cancer Res 23(17):5149–5161CrossRefPubMed Ratti C, Botti L, Cancila V, Galvan S, Torselli I, Garofalo C, Manara MC, Bongiovanni L, Valenti CF, Burocchi A, Parenza M, Cappetti B, Sangaletti S, Tripodo C, Scotlandi K, Colombo MP, Chiodoni C (2017) Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors. Clin Cancer Res 23(17):5149–5161CrossRefPubMed
25.
Zurück zum Zitat Takahashi Y, Yasui T, Tamari K, Minami K, Otani K, Isohashi F, Seo Y, Kambe R, Koizumi M, Ogawa K (2017) Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS One 12(12):e0189697CrossRefPubMedPubMedCentral Takahashi Y, Yasui T, Tamari K, Minami K, Otani K, Isohashi F, Seo Y, Kambe R, Koizumi M, Ogawa K (2017) Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS One 12(12):e0189697CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Lussier DM, Johnson JL, Hingorani P, Blattman JN (2015) Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3:21CrossRefPubMedPubMedCentral Lussier DM, Johnson JL, Hingorani P, Blattman JN (2015) Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3:21CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, Blattman JN (2015) Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 38(3):96–106CrossRefPubMedPubMedCentral Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, Dickman P, Jacobsen J, Hingorani P, Blattman JN (2015) Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 38(3):96–106CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Burgess M, Gorantla V, Weiss K, Tawbi H (2015) Immunotherapy in sarcoma: future horizons. Curr Oncol Rep 17(11):52CrossRefPubMed Burgess M, Gorantla V, Weiss K, Tawbi H (2015) Immunotherapy in sarcoma: future horizons. Curr Oncol Rep 17(11):52CrossRefPubMed
Metadaten
Titel
Evaluation of tumor-infiltrating lymphocytes in osteosarcomas of the jaws: a multicenter study
verfasst von
Pollianna Muniz Alves
José Alcides Almeida de Arruda
Diego Antônio Costa Arantes
Sara Ferreira Santos Costa
Lucas Lacerda Souza
Hélder Antônio Rebelo Pontes
Felipe Paiva Fonseca
Ricardo Alves Mesquita
Cassiano Francisco Weege Nonaka
Elismauro Francisco Mendonça
Aline Carvalho Batista
Publikationsdatum
27.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 2/2019
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-018-2499-6

Weitere Artikel der Ausgabe 2/2019

Virchows Archiv 2/2019 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …